Dewpoint Therapeutics, Inc., a Boston, MA-based biomolecular condensates company, completed a $150m Series C financing.
The round was led by SoftBank Vision Fund 2, along with other new investors General Catalyst, Mubadala Capital, 3E Bioventures, Mirae Asset Capital, and NS Investment. Also joining the round were existing investors Leaps by Bayer, Polaris Partners, Samsara BioCapital, ARCH Venture Partners, EcoR1 Capital, and Maverick Ventures.
Proceeds from the financing will be used to advance multiple pipeline programs through to IND and further invest in Dewpoint’s fully integrated, multi-component biology platform as well as its artificial intelligence-driven data science platform. The company will also expand research infrastructure to support the growth with over 20 pipeline programs in discovery and development spanning oncology, neuromuscular, cardiopulmonary, and virology indications.
Led by Ameet Nathwani, Chief Executive Officer, Dewpoint Therapeutics applies the emerging understanding of biomolecular condensates to drug discovery, with programs spanning oncology, neuromuscular, cardiopulmonary, and virology indications.
Dewpoint scientists work in Boston, Dresden, and Berlin to translate condensate biology into treatments for the toughest diseases.
FinSMEs
03/02/2022